Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists.

Published on Nov 1, 2019
路 DOI :10.1002/hep4.1423
Kathy M. Nilles2
Estimated H-index: 2
(NU: Northwestern University),
Stephen H. Caldwell52
Estimated H-index: 52
(UVA: University of Virginia),
Steven L. Flamm36
Estimated H-index: 36
(NU: Northwestern University)
  • References (47)
  • Citations (0)
馃摉 Papers frequently viewed together
2 Citations
4 Citations
5 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Markus Peck-Radosavljevic (MIT: Massachusetts Institute of Technology)H-Index: 1
#2Krzysztof Simon (Wroc艂aw Medical University)H-Index: 15
Last. Nezam H. Afdhal (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 72
view all 19 authors...
7 CitationsSource
#1Hisashi Hidaka (Kitasato University)H-Index: 15
#2Masayuki KurosakiH-Index: 35
Last. Michio ImawariH-Index: 30
view all 20 authors...
Background & Aims Platelet transfusion is used to prevent hemorrhagic events in patients with thrombocytopenia undergoing invasive procedures, but there are many disadvantages. We evaluated the efficacy and safety of lusutrombopag in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures. Methods We performed a double-blind, parallel-group, phase 3 study of 96 patients with chronic liver disease and thrombocytopenia (platelet counts below 50,000/渭L) undergoing in...
11 CitationsSource
#1Ryosuke Tateishi (UTokyo: University of Tokyo)H-Index: 43
#2Masataka Seike (Oita University)H-Index: 20
Last. Michio ImawariH-Index: 30
view all 15 authors...
Background Thrombocytopenia represents an obstacle for invasive procedures in chronic liver disease (CLD) patients. We aimed to estimate the appropriate dose and evaluate the efficacy and safety of lusutrombopag for the treatment of thrombocytopenia before percutaneous liver radiofrequency ablation (RFA) for primary hepatic cancer in patients with CLD.
17 CitationsSource
#1Janaina Braga Medina (USP: University of S茫o Paulo)H-Index: 1
#2Nat谩lia Silva Andrade (USP: University of S茫o Paulo)H-Index: 2
Last. Karem L贸pez Ortega (USP: University of S茫o Paulo)H-Index: 11
view all 8 authors...
Abstract Little is known about the prevention and management of acquired coagulopathies, such as those affecting cirrhotic patients. The objective of this analytic retrospective observational study was to evaluate patients on the liver transplant waiting list according to the following outcomes: (1) presence of unusual intraoperative bleeding (>10聽min after routine haemostatic procedures); and (2) presence of postoperative haemorrhagic complications. The outcomes were analysed according to clini...
2 CitationsSource
#1Norah A. Terrault (UCSF: University of California, San Francisco)H-Index: 67
#2Yi-Cheng Chen (Memorial Hospital of South Bend)H-Index: 1
Last. Tarek HassaneinH-Index: 47
view all 8 authors...
Abstract Background & Aims Patients with thrombocytopenia and chronic liver disease (CLD) may require platelet transfusions before scheduled procedures to decrease risk of bleeding. We performed 2 randomized, placebo-controlled, phase 3 trials in patients with thrombocytopenia and CLD undergoing scheduled procedures to evaluate the safety and efficacy of avatrombopag in increasing platelet counts in this patient population Methods In the ADAPT-1 and ADAPT-2 studies, adults with thrombocytopenia ...
25 CitationsSource
#1Nicolas M. Intagliata (UVA: University of Virginia)H-Index: 11
#2Curtis K. Argo (UVA: University of Virginia)H-Index: 27
Last. Francesco Violi (Sapienza University of Rome)H-Index: 62
view all 6 authors...
16 CitationsSource
#1Hanny Al-Samkari (Harvard University)H-Index: 6
#2Ariela L. Marshall (Mayo Clinic)H-Index: 11
Last. David J. Kuter (Harvard University)H-Index: 46
view all 4 authors...
10 CitationsSource
#1Jessica P.E. Davis (UVA: University of Virginia)H-Index: 2
#2Patrick G. Northup (UVA: University of Virginia)H-Index: 32
Last. Nicolas M. Intagliata (UVA: University of Virginia)H-Index: 11
view all 4 authors...
Abstract Long thought to be hypocoagulable, new evidence suggests cirrhosis patients have 鈥渞ebalanced鈥 coagulation in the setting of decreased synthesis of both pro- and anti-coagulant factors. Traditional testing like PT/INR reflects only the decreased synthesis of pro-coagulant factors and thus does not correspond to bleeding or clotting risk in this population. In this review, we discuss the use of viscoelastic testing (VET), an assay of global hemostasis in cirrhosis patients. We describe th...
8 CitationsSource
#1Charles A. Schiffer (WSU: Wayne State University)H-Index: 81
#2Kari Bohlke (American Society of Clinical Oncology)H-Index: 10
Last. Kenneth C. Anderson Broyl (Harvard University)H-Index: 162
view all 12 authors...
PurposeTo provide evidence-based guidance on the use of platelet transfusion in people with cancer. This guideline updates and replaces the previous ASCO platelet transfusion guideline published initially in 2001.MethodsASCO convened an Expert Panel and conducted a systematic review of the medical literature published from September 1, 2014, through October 26, 2016. This review builds on two 2015 systematic reviews that were conducted by the AABB and the International Collaboration for Transfus...
37 CitationsSource
#1Masashi Fujita (Fukushima Medical University)H-Index: 4
#2Kazumichi Abe (Fukushima Medical University)H-Index: 15
Last. Hiromasa Ohira (Fukushima Medical University)H-Index: 26
view all 6 authors...
4 CitationsSource
Cited By0